spacer
spacer

PDBsum entry 4mnw

Go to PDB code: 
protein ligands Protein-protein interface(s) links
Hydrolase/hydrolase inhibitor PDB id
4mnw

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
245 a.a.
14 a.a.
Ligands
SO4 ×2
GOL ×5
ACT
ZBR
Waters ×169
PDB id:
4mnw
Name: Hydrolase/hydrolase inhibitor
Title: Crystal structure of urokinase-type plasminogen activator (upa) complexed with bicyclic peptide uk749
Structure: Urokinase-type plasminogen activator chain b. Chain: a. Fragment: catalytic domain (unp residues 179-423). Synonym: u-plasminogen activator, upa. Engineered: yes. Mutation: yes. Bicyclic peptide uk749. Chain: b. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Gene: plau. Expressed in: homo sapiens. Expression_system_taxid: 9606. Expression_system_cell_line: hek 293. Synthetic: yes. Other_details: modified with 1,3,5-tris(bromomethyl)benzene (tbmb)
Resolution:
1.49Å     R-factor:   0.156     R-free:   0.171
Authors: S.Chen,F.Pojer,C.Heinis
Key ref: S.Chen et al. (2014). Peptide ligands stabilized by small molecules. Angew Chem Int Ed Engl, 53, 1602-1606. PubMed id: 24453110 DOI: 10.1002/anie.201309459
Date:
11-Sep-13     Release date:   05-Feb-14    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P00749  (UROK_HUMAN) -  Urokinase-type plasminogen activator from Homo sapiens
Seq:
Struc:
431 a.a.
245 a.a.*
Protein chain
No UniProt id for this chain
Struc: 14 a.a.
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 2 residue positions (black crosses)

 Enzyme reactions 
   Enzyme class: Chain A: E.C.3.4.21.73  - u-plasminogen activator.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: Specific cleavage of Arg-|-Val bond in plasminogen to form plasmin.

 

 
DOI no: 10.1002/anie.201309459 Angew Chem Int Ed Engl 53:1602-1606 (2014)
PubMed id: 24453110  
 
 
Peptide ligands stabilized by small molecules.
S.Chen, D.Bertoldo, A.Angelini, F.Pojer, C.Heinis.
 
  ABSTRACT  
 
Bicyclic peptides generated through directed evolution by using phage display offer an attractive ligand format for the development of therapeutics. Being nearly 100-fold smaller than antibodies, they promise advantages such as access to chemical synthesis, efficient diffusion into tissues, and needle-free application. However, unlike antibodies, they do not have a folded structure in solution and thus bind less well. We developed bicyclic peptides with hydrophilic chemical structures at their center to promote noncovalent intramolecular interactions, thereby stabilizing the peptide conformation. The sequences of the peptides isolated by phage display from large combinatorial libraries were strongly influenced by the type of small molecule used in the screen, thus suggesting that the peptides fold around the small molecules. X-ray structure analysis revealed that the small molecules indeed formed hydrogen bonds with the peptides. These noncovalent interactions stabilize the peptide-protein complexes and contribute to the high binding affinity.
 

 

spacer

spacer